Mitochondrial PD-L1 modulates cancer immunotherapy.
Mitochondrial PD-L1 modulates cancer immunotherapy.
复制标题
线粒体 PD-L1 调节癌症免疫治疗。
DOI：
10.1038/s41422-023-00777-4
复制
发表时间：
2023
期刊：
影响因子：
44.1
通讯作者：
Wei,Wenyi
中科院分区：
文献类型：
--
作者：
Dai,Xiaoming;Liu,Jing;Wei,Wenyi
免疫检查点蛋白PD-L1的表达和亚细胞定位在肿瘤免疫治疗中发挥重要作用。在最近发表于Cell Research的一篇论文中，Xie et al.报告称，通过靶向ATAD 3A-PINK 1-mitophagy轴促进PD-L1的线粒体分布是克服化学免疫疗法耐药性的一种有希望的策略。癌症免疫疗法彻底改变了癌症治疗，对多种类型的人类癌症具有持久的反应，包括三阴性乳腺癌（TNBC）。免疫检查点抑制剂（ICI）如抗PD-1/PD-L1和抗CTLA-4抗体广泛用于临床实践，以激活免疫系统消除癌细胞。然而，总体疗效仍不令人满意，只有某些癌症类型和一部分患者对免疫疗法有反应。虽然化疗已被证明部分通过增加PD-L1表达来提高免疫治疗的疗效，但只有一小部分患者可以从这种联合治疗中获益。迄今为止，许多努力致力于确定内在和获得性耐药机制，以改善对免疫治疗和联合治疗以及其他靶向治疗和/或化疗的临床应答。
The expression and subcellular localization of immune checkpoint protein PD-L1 have been implicated to play an important role in cancer immunotherapy. In a recent paper published in Cell Research, Xie et al. report that promoting mitochondrial distribution of PD-L1 through targeting the ATAD3A-PINK1-mitophagy axis is a promising strategy to overcome chemoimmunotherapy resistance.Cancer immunotherapy has revolutionized cancer treatment with long-lasting responses in multiple types of human cancers, including triple-negative breast cancer (TNBC). Immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are widely used in clinical practices to activate the immune system to eliminate cancer cells. 1 However, the overall efficacy is still unsatisfactory and only certain cancer types and a portion of patients respond to immunotherapy. 1 Although chemotherapy has been proven to improve the efficacy of immunotherapy in part through increasing PD-L1 expression, only a small portion of patients can benefit from such combination therapy. To date, lots of efforts have been devoted to determining the intrinsic and acquired resistant mechanism so as to improve the clinical response to immunotherapy and combination therapy together with other targeted therapy and/or chemotherapy.